Core One Labs, a biotech research and development firm specializing in psychedelic medicines, has secured CAD 0.3 million (USD 0.2 million) through a loan agreement with Right Season Investments. The loan carries an annual interest rate of 15% and is repayable on demand.
The new funds will be allocated toward general administrative costs and working capital.
Analyst QuickTake: Core One previously secured CAD 1.5 million (USD 1.1 million) via private placement in April 2024 for working capital and general corporate purposes.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.